Business Context and Reporting Period
Company: Cardo Medical, Inc. (Note: Request metadata listed "Biocardia, Inc.", but the filing text identifies the registrant as Cardo Medical, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: An orthopedic medical device company specializing in reconstructive joint devices (knee, hip) and spinal surgical devices. The company operates through two segments: Reconstructive Division and Spine Division.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Net Sales | $1,979,000 | $878,000 |
| Gross Profit | $1,586,000 | $708,000 |
| Gross Margin | 80.1% | 80.6% |
| Net Loss | $(2,937,000) | $(2,563,000) |
| Cash Flow from Operations | $(2,593,000) | $(2,207,000) |
| Cash and Equivalents (End of Period) | $1,665,000 | $3,250,000 |
| Total Assets | $13,720,000 | $15,588,000 |
| Accumulated Deficit | $(14,102,000) | $(11,165,000) |
Debt and Liquidity: The filing does not disclose long-term debt. Current liabilities consist primarily of accounts payable and accrued expenses ($1,884,000). Working capital is positive but declining due to cash burn.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 125% year-over-year (from $878k to $1.98m). This was driven by a 1,565% increase in Spine Division sales ($54k to $890k) due to the introduction of interbody spinal devices, and a 32% increase in Reconstructive Division sales.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 28% ($3.08m to $3.96m) due to higher sales commissions, professional fees for strategic opportunities, and expanded office space. R&D expenses nearly tripled ($206k to $599k) due to increased labor and custom instrumentation.
- Cash Position: Cash decreased by $3.3 million during the six-month period. Unlike the prior year, there were no proceeds from financing activities (private placements) in the first half of 2010.
- Inventory Build-up: Inventory increased by $1.13 million, representing a significant use of cash to support anticipated sales growth.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management explicitly states there is "substantial doubt about the Company's ability to continue as a going concern." The company anticipates sustaining losses through Q4 2010 and requires additional capital to supplement operations.
- Financing Needs: Current cash reserves are projected to meet needs only through the third fiscal quarter of 2010. Management is actively seeking financing but notes no assurance that funds will be available on favorable terms.
- Segment Performance: Both the Reconstructive and Spine divisions generated positive net income on a segment basis ($227k and $695k respectively for the six months), but these were overwhelmed by corporate-level operating expenses ($3.86m loss).
- Risks: Key risks include dependence on third-party payors for reimbursement, reliance on single-source manufacturers, potential patent litigation, and the need for continued equity or debt financing to avoid scaling back operations.
Investor Verification Checklist
- Capital Runway: Verify the timeline for securing new financing, as current cash ($1.665m) may not sustain operations beyond Q3 2010.
- Customer Concentration: Review the top three customers, who accounted for 46.3% of net sales in the six months ended June 30, 2010.
- Inventory Valuation: Assess the $1.13 million increase in inventory to ensure it aligns with actual sales velocity and is not at risk of obsolescence.
- Corporate Overhead: Analyze the $3.86 million corporate loss to determine if cost-cutting measures are feasible without stalling growth.
- Stock Dilution: Monitor for potential equity issuances, as the company has historically funded operations through private placements and has 230 million shares outstanding.